Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infant immunogenicity study of Infanrix-Hexa versus Vaxelis given with Bexsero
2018-003451-38Phase 4Unknown
- Sponsor
- Clinical Trials and Research Governance
- Start
- Jan 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Infanrix Hexa, DTaP-IPV-Hep B-PRP-T vaccine and meningococcal group B vaccine in Haemophilus influenzae type b disease (Hib), meningococcal disease, pneumococcal disease and 9 more (2 arms), sponsored by Clinical Trials and Research Governance. Primary endpoint: Primary immunogenicity endpoint. Status: unknown.
02
Drugs
Infanrix HexaDTaP-IPV-Hep B-PRP-T vaccinemeningococcal group B vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal diseasepneumococcal diseasehepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2018-003451-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003451-38.